Juvenile Idiopathic Arthritis (JIA)
Conditions
Keywords
Juvenile idiopathic arthritis (JIA), JIA patients in transition towards adult ward, Prognosis of JIA, Severity and structural damage in JIA, Angiogenic and inflammatory biomarkers, Semaphorin (SEMA4A), CCN1, Serum fluid, Synovial fluid
Brief summary
The aim of the study is to determine whether serum inflammatory angiogenic markers (eg, semaphorins, CCN1) predict severity of juvenile idiopathic arthritis defined by structural progression and/or therapeutic escalation.
Detailed description
Juvenile idiopathic arthritis (JIA) is a heterogeneous group of chronic inflammatory rheumatic diseases beginning before the age of 16. The most common pediatric rheumatologic disease. JIA is the most common pediatric rheumatologic disease. Apart from clinical features and the biological inflammatory syndrome, no predictive parameter for the severity of JIA, especially polyarticular JIA, has been identified. The team has been interested in the prognosis of RA for many years. Thus, the investigators have conducted various studies in search of biological parameters associated with the joint prognosis of RA patients, which allowed the investigator to discover the interest of angiogenic and inflammatory biomarkers such as semaphorins and CCN1 protein. This has been demonstrated in vitro but also in vivo from sera of RA patients. These markers are associated with activity and structural damage in RA. The project aims to study the interest of these same angiogenic biomarkers in the serum of JIA patients in order to establish whether, as in RA, they are also associated with disease severity.
Interventions
BIOLOGICALBlood sample
Addtional tube of blood needed for follow up of patients
BIOLOGICALJoint puncture
Joint puncture if needed according to routine care of the patients
Sponsors
URC-CIC Paris Descartes Necker Cochin
Assistance Publique - Hôpitaux de Paris
Study design
Observational model
COHORT
Time perspective
PROSPECTIVE
Eligibility
Sex/Gender
ALL
Age
16 Years to No maximum
Healthy volunteers
No
Inclusion criteria
* Greater than or equal to 16 years-old * Diagnosis of Juvenile Idiopathic Arthritis with specialized follow up in Rheumatology at Cochin Hospital * No-opposition to the research * Patient with health insurance * Mastery of the French language
Exclusion criteria
* Patient under curatorship or guardianship * Patient receiving french state medical aid
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Dosage of angiogenic markers | 5 years | Dosage of angiogenic markers by ELISA method in serum. Determine if angiogenic and inflammatory biomarkers are predictive of a more severe disease as reflected by structural joint damage and treatments received. Activity measured with questionnaires, and treatments received. Structural damage determined by x-rays during follow up. |
| Dosage of inflammatory markers by ELISA method | 5 years | Dosage of inflammatory markers by ELISA method in serum. Determine if angiogenic and inflammatory biomarkers are predictive of a more severe disease as reflected by structural joint damage and treatments received. Activity measured with questionnaires, and treatments received. Structural damage determined by x-rays during follow up. |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Structural damage determined by x-rays | 5 years | Structural damage determined by x-rays during follow up. |
| Questionnaires | 5 years | Severity of JIA |
| Inflammatory biomarkers | At inclusion | Determine if sera inflammatory biomarkers are associated with clinical subtypes of JIA. |
| Angiogenic biomarkers | At inclusion | Determine if sera angiogenic biomarkers are associated with clinical subtypes of JIA. |
| Collection of treatments received | 5 years | Severity of JIA |
Countries
France
Contacts
Primary ContactYannick ALLANORE, PD, PhD
Backup ContactMarie BENHAMMANI-GODARD
Outcome results
None listed